Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Lomedeucitinib with Rosuvastatin, Metformin, and Methotrexate
NCT05615012Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lomedeucitinib in psoriasis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 21 days, Area under the plasma concentration-time curve from time zero extrapolated to infinite time up to 21 days and 1 more. Started Nov 2022; status: completed.
02
Drugs
lomedeucitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05615012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615012.